Propionyl-l-Carnitine in Leriche-Fontaine Stage II Peripheral Arterial Obstructive Disease

Annals of Vascular Surgery

Volumn 22, Issue 4, 2008, Pages 552-558

  Allegra, Claudio ^a   Antignani, Pier Luigi ^a   Schachter, Ilana ^a   Koverech, Aleardo ^b   Messano, Masa ^b   Virmani, Ashraf ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b Scientific Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE DERIVATIVE; FLUORESCEIN SODIUM; PROPIONYL CARNITINE; SODIUM CHLORIDE;

AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CAPILLAROSCOPY; CAPILLARY; CLINICAL ARTICLE; CLINICAL STUDY; CONTINUOUS INFUSION; CONVALESCENCE; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HOMEOSTASIS; HUMAN; ISCHEMIA; LEG; LEG ARTERY; LERICHE FONTAINE STAGE; MALE; MICROCIRCULATION; MICROVASCULATURE; MUSCLE CONTRACTION; PAIN; PARAMETER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SKELETAL MUSCLE; TIME; TREADMILL; TREATMENT DURATION; TREATMENT INDICATION; WALKING;

AGED; ARTERIAL OCCLUSIVE DISEASES; BLOOD FLOW VELOCITY; CARDIOVASCULAR AGENTS; CARNITINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEG; MALE; MICROCIRCULATION; MICROSCOPIC ANGIOSCOPY; MUSCLE, SKELETAL; PERIPHERAL VASCULAR DISEASES; WALKING;

EID: 46649113319     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2008.02.010     Document Type: Article

References (35)

1. Brevetti G., Silvestro A., Schiano V., et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 108 (2003) 2093-2098
2. Fontaine R., Kieny R., Gangloff J.M., et al. Long-term results of restorative arterial surgery in obstructive diseases of the arteries. J Cardiovasc Surg 5 (1964) 463-472
3. Hirsch A.T. Claudication as an "orphan disease": rationale and goals of drug therapy for peripheral arterial disease. Vasc Med 1 (1996) 37-42
4. Hiatt W.R., Nawaz D., and Brass E.P. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 62 (1987) 2383-2387
5. Hiatt W.R., Wofel E.E., Regensteiner J.G., et al. Skeletal muscle carnitine metabolism in patients with unilateral peripheral vascular disease. J Appl Physiol 73 (1992) 346-353
6. Kannel W.B. The demographics of claudication and the aging of the American population. Vascular Med 1 (1996) 60-64
7. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 27 (2007) 266-274
8. Brevetti G., Diehm C., and Lambert D. European multicenter study on propionyl-l-carnitine in intermittent claudication. J Am Coll Cardiol 34 (1999) 1618-1624
9. Anand I., Chandrashekhan Y., De Giuli F., et al. Acute and chronic effects of propionyl-l-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 12 (1998) 291-299
10. Binienda Z., and Virmani A. The mitochondriotropic effects of l-carnitine and its esters in the central nervous system. Curr Med Chem 3 (2003) 275-282
11. Wiseman L.R., and Brogden R.N. Propionyl-l-carnitine. Drugs Aging 12 (1998) 243-248
12. Brass E.P., and Hiatt W.R. The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. J Am Coll Nutr 17 (1998) 207-215
13. Hiatt W.R. Treatment of disability in peripheral arterial disease: new drugs. Curr. Drug Targets Cardiovasc Haematol Disord 4 (2004) 227-231
14. Antignani P.L. Treatment of chronic peripheral arterial disease. Curr Vasc Pharmacol 1 (2003) 205-216
15. Hiatt W.R., Regensteiner J.G., Creager M.A., et al. Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110 (2001) 616-622
16. Allegra C., Bartolo Jr. M., Barioti B., and Cassiani D. Lymphatic capillaries pressure in human skin of patients with chronic venous insufficiency. Int J Microcirc 9 (1994) 341-349
17. Endemann D.H., and Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 15 (2004) 1983-1992
18. Virmani A., Binienda Z., Ali S., and Gaetani F. Links between nutrition, drug abuse, and the metabolic syndrome. Ann N Y Acad Sci 1074 (2006) 303-314
19. Hayden M.R., Sowers J.R., and Tyagi S.C. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol 4 (2005) 9
20. Nishiyama A., Rahman M., and Inscho E.W. Role of interstitial ATP and adenosine in the regulation of renal hemodynamics and microvascular function. Hypertens Res 27 (2004) 791-804
21. Verhamme P., and Hoylaerts M.F. The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belg 61 (2006) 213-219
22. Ellis C.G., Jagger J., and Sharpe M. The microcirculation as a functional system. Crit Care 9 (2005) S3-S8
23. Hiatt W.R. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 1033 (2004) 92-98
24. Ferrari R., Merli E., Cicchitelli G., Mele D., Fucili A., and Ceconi C. Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 1033 (2004) 79-91
25. Corsi C., Pollastri M., Marrapodi E., et al. l-Propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease. Angiology 46 (1995) 705-713
26. Brevetti G., Di Lisa F., Perna S., et al. Carnitine-related alterations in patients with intermittent claudication. Indication for a focused carnitine therapy. Circulation 93 (1996) 1685-1689
27. Arenas J., Ricoy J.R., Encinas A.R., et al. Carnitine in muscle, serum, and urine of nonprofessional athletes: effects of physical exercise, training, and l-carnitine administration. Muscle Nerve 14 (1991) 598-604
28. Arduini A., Gorbunov N., Arrigoni-Martelli E., et al. Effects of l-carnitine and its acetate and propionate esters on the molecular dynamics of human erythrocyte membrane. Biochim Biophys Acta 1146 (1993) 229-235
29. Brevetti G., Corrado S., Martone V.D., et al. Microcirculation and tissue metabolism in peripheral arterial disease. Clin Hemorheol Microcirc 21 (1999) 245-254
30. Felix C., Gillis M., Driedzic W.R., et al. Effects of propionyl-l-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart. Diabetes Res Clin Pract 53 (2001) 17-24
31. 31P magnetic resonance spectroscopy: a phase II open study. Vasc Med 1 (1996) 241-245
32. Thompson C.H., Irish A.B., Kemp G.J., et al. The effect of propionyl l-carnitine on skeletal muscle metabolism in renal failure. Clin Nephrol 47 (1997) 372-378
33. 31Phosphorus magnetic resonance spectroscopy to evaluate medical therapy efficacy in peripheral arterial disease. A pilot study. Panminerva Med 41 (1999) 283-290
34. Reznick A.Z., Kagan V.E., Ramsey R., et al. Antiradical effects in l-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation. Arch Biochem Biophys 296 (1992) 394-401
35. Cipolla M.J., Nicoloff A., Rebello T., et al. Propionyl-l-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg 29 (1999) 1097-1103